SYDNEY, AUSTRALIA – DECEMBER 2024 – Novotech, the global full-service clinical Contract Research Organization (CRO), announces the release of its report, Parkinson’s Disease: Global Clinical Trial Landscape 2024. This report provides critical insights into the trends, opportunities, and challenges in Parkinson's disease (PD) research, serving as a valuable resource for companies developing treatments for this complex neurodegenerative disorder.
Report Highlights
Parkinson’s disease is one of the fastest-growing neurological conditions, with prevalence expected to double by 2030. This report analyzes global clinical trial data, offering biotech and pharmaceutical companies key information to guide clinical development strategies. Key findings include:
- Global Trial Distribution: Review of over 750 PD trials initiated since 2019, with Asia-Pacific leading at 44% of trials. Major regions include China, the U.S., and Europe, reflecting current research priorities.
- Therapeutic Innovation: Overview of emerging approaches, such as gene therapy, deep brain stimulation, and cell-based therapies aimed at modifying disease progression and improving patient outcomes.
- Pipeline Insights: Analysis of 145 preclinical and 64 clinical-stage drug candidates highlights a diverse therapeutic pipeline in various stages of development.
- Regional Recruitment and Trial Duration: Europe shows higher recruitment efficiency, while Asia-Pacific indicates a need for increased trial density, highlighting operational challenges and opportunities across regions.
Understanding PD’s Growing Impact
The report also explores genetic, epidemiological, and socioeconomic factors influencing PD’s global burden. These insights are essential for companies looking to design targeted, region-specific clinical trials that consider varying patient needs and regulatory requirements.
This report serves as a practical resource for the PD research community, providing actionable insights to support efficient, effective clinical trials.
Gain a comprehensive understanding of the Parkinson’s disease clinical trial landscape and access actionable insights to support your development goals. Download the full report to inform your strategies in PD research and clinical trials.
Media contact
Toyna Chin
노보텍(Novotech) 소개
1997년 설립된 노보텍은 글로벌 full-service CRO이며 바이오텍과 제약회사와의 파트너십을 통해 임상의 모든 단계에서 혁신적이면서도 새로운 치료제 개발을 가속하는 데 주력하고 있습니다.
노보텍은 CRO 업계에서의 선도적인 역할을 인정받아 다수의 권위 있는 상을 수상하였습니다. 2024년에는 Frost & Sullivan의 Global Biotech CRO Award, Clinical Trials Arena Award for Excellence in Business Expansion, Marketing, and Innovation, Employer of Choice, 미국 Great Place to Work 인증, Brandon Hall Gold Award를 수상하였으며, 2023년에는 CRO Leadership Award와 Asia Pacific Cell & Gene Therapy Clinical Trials Excellence를 수상하였습니다. 또한, 2006년부터 Asia-Pacific Contract Research Organization Company of the Year Award를 수상하며 업계에서의 입지를 공고히 하고 있습니다.
노보텍은 연구소, 임상 1상 시험 기관, 약물 개발 컨설팅 서비스, 규제 전문성 등 종합적인 서비스를 제공하며, 1상에서 4상까지의 임상시험과 생물학적 동등성 연구를 포함해 5000건 이상의 임상 프로젝트에 참여한 경험이 있습니다. 노보텍은 전 세계 지역에 걸쳐 34개 지사와 3000명 이상의 직원을 두고 있으며 신뢰할 수 있는 완전한 형태의 전략 파트너입니다.
더 자세한 정보나 임상시험 관련 상담을 원하신다면, 노보텍 공식 웹사이트를 (www.Novotech-CRO.com) 방문하시기 바랍니다.